Latest news with #Alector
Yahoo
5 days ago
- Business
- Yahoo
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET. A live webcast of the fireside chat will be available on the 'Events & Presentations' page within the Investors section of the Alector website at A replay will be available on the Alector website for 90 days following the event. About AlectorAlector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit Alector Contacts: AlectorKatie Argot Partners (media)David Rosen646-461-6387alector@ Argot Partners (investors)Laura Perry212-600-1902alector@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
12-05-2025
- Business
- Business Insider
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Iovance Biotherapeutics (IOVA)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM – Research Report), Iovance Biotherapeutics (IOVA – Research Report) and Alector (ALEC – Research Report) with bullish sentiments. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Axsome Therapeutics (AXSM) Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics yesterday and set a price target of $190.00. The company's shares closed last Friday at $107.76. According to Purohit is a 1-star analyst with an average return of -4.1% and a 37.7% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, BioMarin Pharmaceutical, and Arcutis Biotherapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axsome Therapeutics with a $176.07 average price target, a 61.7% upside from current levels. In a report issued on April 29, RBC Capital also maintained a Buy rating on the stock with a $193.00 price target. Wells Fargo analyst Yanan Zhu maintained a Buy rating on Iovance Biotherapeutics on May 9 and set a price target of $18.00. The company's shares closed last Friday at $1.75. According to Zhu has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.6% and a 26.4% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Crispr Therapeutics AG, and Taysha Gene Therapies. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Iovance Biotherapeutics with a $13.83 average price target, representing a 612.9% upside. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target. Alector (ALEC) BTIG analyst Thomas Shrader maintained a Buy rating on Alector on May 9 and set a price target of $5.00. The company's shares closed last Friday at $1.17. According to Shrader is a 2-star analyst with an average return of 0.2% and a 33.8% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Acumen Pharmaceuticals, and Arcturus Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alector with a $5.50 average price target, which is a 428.8% upside from current levels. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock.
Yahoo
10-05-2025
- Business
- Yahoo
Alector First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Revenue: US$3.67m (down 77% from 1Q 2024). Net loss: US$40.5m (loss widened by 12% from 1Q 2024). US$0.41 loss per share (further deteriorated from US$0.39 loss in 1Q 2024). Our free stock report includes 3 warning signs investors should be aware of before investing in Alector. Read for free now. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 14%. Earnings per share (EPS) exceeded analyst estimates by 17%. Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 10.0% from a week ago. We should say that we've discovered 3 warning signs for Alector that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
Alector First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Revenue: US$3.67m (down 77% from 1Q 2024). Net loss: US$40.5m (loss widened by 12% from 1Q 2024). US$0.41 loss per share (further deteriorated from US$0.39 loss in 1Q 2024). Our free stock report includes 3 warning signs investors should be aware of before investing in Alector. Read for free now. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 14%. Earnings per share (EPS) exceeded analyst estimates by 17%. Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 10.0% from a week ago. We should say that we've discovered 3 warning signs for Alector that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
17-04-2025
- Business
- Yahoo
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease
--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD). Alector and GSK are co-developing AL101, an investigational human monoclonal antibody designed to block and downregulate the sortilin receptor to elevate progranulin (PGRN) levels in the brain. Modest reductions in PGRN levels due to GRN gene mutations have been shown to be associated with an increased risk of developing AD.1, 2, 3 Conversely, elevated PGRN levels have been shown to be protective in animal models of AD.4 'In partnership with GSK, we are pleased to announce the completion of enrollment ahead of schedule in the PROGRESS-AD Phase 2 clinical trial of AL101, marking an important milestone in our pursuit of developing first-in-class therapies for Alzheimer's disease,' said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. 'This achievement brings us one step closer to assessing the potential of AL101 in slowing disease progression and to furthering our understanding of AL101's effects on individuals living with this devastating condition. We remain committed to advancing our progranulin-elevating candidate and evaluating its impact in the ongoing trial.' PROGRESS-AD is a randomized, double-blind, placebo-controlled Phase 2 clinical trial of AL101, which GSK is conducting at multiple sites globally. Two dose levels of AL101 are being evaluated in the trial, with participants randomized to receive either AL101 or placebo intravenously. The primary endpoint of the study is disease progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB). The CDR-SB is a validated instrument that tracks the progression of cognitive impairments in various categories. The trial also measures other clinical and functional outcome assessments. Additional information about PROGRESS-AD (NCT06079190) may be found at About AL101/ GSK4527226AL101/GSK4527226 is an investigational human monoclonal antibody designed to block and downregulate the sortilin receptor to elevate progranulin (PGRN) levels in the brain. PGRN, a protein encoded by the GRN gene, regulates lysosomal function, neuronal survival, and inflammation. The protein is genetically linked to multiple neurodegenerative disorders. Alector and GSK are co-developing AL101 for the potential treatment of early Alzheimer's disease (AD), and it may also be evaluated for other indications, including Parkinson's disease (PD). Given PGRN's genetic association with neurodegeneration, elevating PGRN levels may provide a potential therapeutic approach that offers broad neuroprotection in both AD and PD. Collaboration with GSKIn July 2021, Alector entered into a collaboration and license agreement with GSK (LSE/NYSE: GSK) to collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101/GSK4527226. Under the terms of the GSK agreement, Alector received $700 million in upfront payments. In addition, Alector may be eligible to receive up to an additional $1.5 billion in clinical development, regulatory, and commercial launch-related milestone payments. In the United States, the companies will equally share profits and losses from commercialization of latozinemab and AL101. Outside of the United States, Alector will be eligible for double-digit tiered royalties. About AlectorAlector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, blood-brain barrier technology platform, research and preclinical pipeline, planned and ongoing preclinical studies and clinical trials, anticipated timing of PROGRESS-AD, expected milestones, expectations of our collaboration with GSK, expectations of our interactions with regulatory authorities, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector's Annual Report on Form 10-K filed for 2024, with the Securities and Exchange Commission ('SEC'), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector's forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law. REFERENCES Bellenguez, C., et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat. Genet. 2022, 54, 412–436. Brouwers, N, et al. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology. 2008, 71, 656–664. Fenoglio, C, et al. Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. J. Alzheimer's Dis. 2009, 18, 603–612 Minami, S.S; et al. Progranulin protects against amyloid beta deposition and toxicity in Alzheimer's disease mouse models. Nat. Med. 2014, 20, 1157–1164. Alector Contacts: Alector Katie Hogan Argot Partners (media)David Rosen646-461-6387alector@ Argot Partners (investors)Laura Perry212-600-1902alector@ in to access your portfolio
